Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Management of High Blood Pressure Immediately After Stroke

24.06.2008
A research project at the University of Leicester in conjunction with the University of East Anglia, indicates that early reduction of high blood pressure following stroke is feasible and safe, and both Labetalol & Lisinopril were found to be suitable a medications for this purpose.

Larger studies will now be necessary to confirm this result and test the effects on recovery from stroke.

Amit Mistri, a postgraduate researcher working on this project commented: “Stroke is a debilitating condition with high death and dependency rates. There are many unanswered dilemmas in the early management of people who have suffered a stroke.

“For early treatment of strokes caused by a clot in the circulation, aspirin is the only medication shown to be beneficial (small benefit), and clot-dissolving treatment (thrombolysis) is applicable to a minority only. No evidence-based treatment exists for early management of strokes secondary to bleeding within the brain. Elevated blood pressure represents a new therapeutic target in the early management of both types of stroke.”

The research was funded and sponsored by the National Health Service Research and Development Health Technology Assessment Programme of the Department of Health.

Elevated peak arterial blood pressure (systolic blood pressure - SBP) following a stroke has been associated with worse outcome. It is not known whether early lowering of high SBP would be beneficial in improving outcome following stroke.

The research in Leicester was carried out as part of CHHIPS, a multicentre UK-based study, which compared the SBP lowering efficacy of two medications (labetalol and lisinopril) with dummy medication (placebo).

179 patients with high SBP (>160 mmHg) were randomly allocated to receive labetalol, lisinopril or a placebo. The dose was increased over the first 12 hours to attain a pre-specified SBP target, and continued for 2 weeks. Alternative formulations were available for those unable to swallow.

From a baseline SBP of 182 mmHg, average reduction of SBP at 24 hours in the individual groups was: labetalol-18, lisinopril-25, and placebo-11 mmHg. Active medication reduced SBP more than placebo at 24 hours. Both medications studied were not associated with an increase in further deterioration or adverse effects, compared to placebo.

Amit Mistri developed an interest in stroke research, during his training in Geriatric Medicine. The research was carried out in the Ageing & Stroke Medicine section of the Department of Cardiovascular Sciences, where he was a clinical research fellow, and the trial coordinator for the multi-centre CHHIPS study. His interests include: blood pressure in acute stroke, participation of stroke patients in research trials, epidemiology of stroke, and risk factor modification for secondary prevention of stroke.

The research is being presented to the public at the University of Leicester on Thursday 26th June. The Festival of Postgraduate Research introduces employers and the public to the next generation of innovators and cutting-edge researchers, and gives postgraduate researchers the opportunity to explain the real world implications of their research to a wide ranging audience.

More information about the Festival of Postgraduate Research is available at: www.le.ac.uk/gradschool/festival

Ather Mirza | alfa
Further information:
http://www.le.ac.uk/gradschool/festival

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

Camera on NASA's Lunar Orbiter survived 2014 meteoroid hit

29.05.2017 | Physics and Astronomy

Strathclyde-led research develops world's highest gain high-power laser amplifier

29.05.2017 | Physics and Astronomy

A 3-D look at the 2015 El Niño

29.05.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>